TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10720118

Group type: EXPERIMENTAL
Intervention: Short-chain fatty acids (SCFA) enema administered twice daily for 3 weeks
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo solution administered twice daily for 3 weeks
Number of subjects: 9
Study: 8737132

Group type: EXPERIMENTAL
Intervention: Sparfloxacin (200 mg on day 1 followed by 100 mg daily for 6 additional days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sparfloxacin (200 mg on day 1 followed by 100 mg daily for 2 additional days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Doxycycline (200 mg once daily for 7 days)
Number of subjects: 0
Study: 1343113

Group type: EXPERIMENTAL
Intervention: 15 mg dexfenfluramine (dF) twice daily for 3 days prior to glucose infusion; 30 mg dF 90 min before the test.
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 30 mg dexfenfluramine (dF) before the test.
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: dF treatment in obese subjects for one month.
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: dF treatment in obese subjects with relative fasting hyperinsulinemia (> 100 pmol/l).
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: dF treatment in obese subjects with low fasting plasma insulin (< 100 pmol/l).
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo treatment.
Number of subjects: 29
Study: 2857709

Group type: EXPERIMENTAL
Intervention: trimipramine
Number of subjects: 25

Group type: COMPARATOR
Intervention: doxepin
Number of subjects: 25
Study: 31442786

Group type: EXPERIMENTAL
Intervention: Tub bathing
Number of subjects: 120

Group type: COMPARATOR
Intervention: Sponge bathing
Number of subjects: 120
Study: 29022125

Group type: EXPERIMENTAL
Intervention: Atomoxetine (ATX) alone
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo alone
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Atomoxetine (ATX) + Parent Training (PT)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Parent Training (PT) + Placebo
Number of subjects: 128
Study: 26700705

Group type: EXPERIMENTAL
Intervention: Interferon alpha-2b (IFN) 3 × 10(6) IU subcutaneously 3 times a week for 4 weeks and 13-cis-retinoic acid (RA) 40 mg orally daily for 30 days during radiation therapy
Number of subjects: 209

Group type: COMPARATOR
Intervention: Cisplatin 40 mg/m(2) weekly for 5 weeks during radiation therapy
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Disease-free survival
Number of subjects: 209

Group type: COMPARATOR
Intervention: Acute toxicities of chemoradiation
Number of subjects: 209
Study: 24154987

Group type: EXPERIMENTAL
Intervention: Self-affirmation manipulation (affirmation)
Number of subjects: 236

Group type: COMPARATOR
Intervention: Self-affirmation manipulation (no affirmation)
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Implementation intention manipulation (implementation intention)
Number of subjects: 236

Group type: COMPARATOR
Intervention: Implementation intention manipulation (no implementation intention)
Number of subjects: 236
Study: 23098013

Group type: EXPERIMENTAL
Intervention: Hospice volunteer program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-participants (control group)
Number of subjects: 0
Study: 20117403

Group type: EXPERIMENTAL
Intervention: Serum sST2 levels measured at baseline and at 12 and 24 weeks
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Serum sST2 levels
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Change in sST2 levels
Number of subjects: 100
Study: 18022679

Group type: EXPERIMENTAL
Intervention: Acute nicotine (7 mg patch for 45 min)
Number of subjects: 15
Study: 15901750

Group type: EXPERIMENTAL
Intervention: 60% ethanolic extract from the roots of Echinacea angustifolia, 2.5-mL dose
Number of subjects: 11
Study: 12934777

Group type: EXPERIMENTAL
Intervention: Extended-release oxybutynin 10 mg/d
Number of subjects: 790

Group type: COMPARATOR
Intervention: Extended-release tolterodine 4 mg/d
Number of subjects: 790
Study: 10822316

Group type: EXPERIMENTAL
Intervention: losartan 50-100 mg/day (n = 15)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: enalapril 2.5-10 mg/day (n = 14)
Number of subjects: 29
Study: 8867163

Group type: EXPERIMENTAL
Intervention: Midazolam 3.75 mg
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 1518695

Group type: EXPERIMENTAL
Intervention: Surfactant therapy during clinical trial participation
Number of subjects: 0
Study: 6712393

Group type: EXPERIMENTAL
Intervention: Continuous infusion of tobramycin plus cefamandole
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Interrupted infusion of tobramycin plus cefamandole
Number of subjects: 64

Group type: COMPARATOR
Intervention: Continuous infusion of tobramycin
Number of subjects: 64

Group type: COMPARATOR
Intervention: Interrupted infusion of tobramycin
Number of subjects: 64
Study: 31730643

Group type: EXPERIMENTAL
Intervention: Incremental Theory of Personality Intervention (ITPI)
Number of subjects: 858

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 858
Study: 28079236

Group type: EXPERIMENTAL
Intervention: CHO beverage (12.5% maltodextrin)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: CHO-GLN beverage (12.5% maltodextrin plus 15 g GLN)
Number of subjects: 20
Study: 26841875

Group type: EXPERIMENTAL
Intervention: interpersonal psychotherapy (IPT) + treatment as usual (TAU)
Number of subjects: 200

Group type: COMPARATOR
Intervention: treatment as usual (TAU)
Number of subjects: 200
Study: 24220914

Group type: EXPERIMENTAL
Intervention: FOBT (+) group
Number of subjects: 165

Group type: COMPARATOR
Intervention: FOBT (-) group
Number of subjects: 165
Study: 22538183

Group type: EXPERIMENTAL
Intervention: Oral cannabis brief intervention
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Written cannabis brief intervention
Number of subjects: 134

Group type: COMPARATOR
Intervention: Health controls
Number of subjects: 134
Study: 20716619

Group type: EXPERIMENTAL
Intervention: Computer-tailored decision aid (DA)
Number of subjects: 625

Group type: COMPARATOR
Intervention: Nonintervention comparison condition
Number of subjects: 625
Study: 17563866

Group type: EXPERIMENTAL
Intervention: Low-dose, weekly docetaxel chemotherapy
Number of subjects: 1
Study: 16340380

Group type: EXPERIMENTAL
Intervention: DHEA
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 11263614

Group type: EXPERIMENTAL
Intervention: Implantable Cardiac Defibrillator (ICD)
Number of subjects: 491

Group type: COMPARATOR
Intervention: Antiarrhythmic drug therapy (Amiodarone)
Number of subjects: 491
Study: 9623426

Group type: COMPARATOR
Intervention: Local anaesthetics (1 ml kg‐1 of a mixture of 0.25% bupivacaine with epinephrine and 1% lidocaine in equal parts)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Local anaesthetics + fentanyl 1 microgram kg‐1
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Local anaesthetics + clonidine 1.5 micrograms kg‐1
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Local anaesthetics + fentanyl 0.5 microgram kg‐1 and clonidine 0.75 microgram kg‐1
Number of subjects: 64

Group type: COMPARATOR
Intervention: Local anaesthetics (control group)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Local anaesthetics + additives (fentanyl or clonidine)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Fentanyl (in any group)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Clonidine (in any group)
Number of subjects: 64
Study: 7522646

Group type: EXPERIMENTAL
Intervention: Intracavitary mitoxantrone
Number of subjects: 41

Group type: COMPARATOR
Intervention: Intracavitary bleomycin
Number of subjects: 41
Study: 3830246

Group type: EXPERIMENTAL
Intervention: Digoxin 0.25 to 0.88 mg daily
Number of subjects: 10
Study: 29289332

Group type: EXPERIMENTAL
Intervention: 100μg levothyroxine sodium tablet once daily for 6 months
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Tablet dissolution rate (BP/EP 2014 & USP 2014)
Number of subjects: 50
Study: 27280850

Group type: EXPERIMENTAL
Intervention: Aflibercept (2.0 mg)
Number of subjects: 624

Group type: EXPERIMENTAL
Intervention: Ranibizumab (0.3 mg)
Number of subjects: 624
Study: 25062861

Group type: EXPERIMENTAL
Intervention: Virtual visits via web‐based video conferencing
Number of subjects: 13
Study: 23224567

Group type: COMPARATOR
Intervention: Sham treatment followed by balloon treatment (group 1)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Balloon treatment (group 2)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 42
Study: 21590260

Group type: EXPERIMENTAL
Intervention: Constant-velocity ramps
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Half-cycle sinusoids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Short duration segments (240 ms)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-frequency components associated with short duration segments
Number of subjects: 0
Study: 18754987

Group type: EXPERIMENTAL
Intervention: Perinatal home visiting interventions (not specifically designed to address intimate partner violence)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Home visiting interventions addressing intimate partner violence in nonperinatal population groups
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perinatal home visiting programs with specific intimate partner violence interventions
Number of subjects: 0
Study: 17058610

Group type: EXPERIMENTAL
Intervention: Bipolar resection (Olympus ch 26, 30 degrees)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Monopolar resection (Storz Ch 26, 30 degrees)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 45
Study: 12928051

Group type: EXPERIMENTAL
Intervention: ‐174 C allele in the promoter region of IL‐6 gene
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ‐174 CC genotype
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: D allele of VNTR
Number of subjects: 0

Group type: COMPARATOR
Intervention: VNTR C allele
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ‐174 CC and VNTR DD genotypes
Number of subjects: 0
Study: 10843430

Group type: EXPERIMENTAL
Intervention: Fexofenadine 180 mg
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 9596934

Group type: EXPERIMENTAL
Intervention: Risk factor scoring model for STD
Number of subjects: 1656
Study: 8561526

Group type: EXPERIMENTAL
Intervention: Praziquantel (40 mg/kg)
Number of subjects: 377

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 377
Study: 6605565

Group type: EXPERIMENTAL
Intervention: Rifampin 20 mg/kg once daily for four days
Number of subjects: 1467

Group type: EXPERIMENTAL
Intervention: Rifampin (other regimens)
Number of subjects: 1467

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1467

Group type: EXPERIMENTAL
Intervention: Rifampin (for contacts younger than age five)
Number of subjects: 1467
Study: 31362674

Group type: EXPERIMENTAL
Intervention: Levetiracetam
Number of subjects: 136

Group type: COMPARATOR
Intervention: Valproate
Number of subjects: 136
Study: 29793698

Group type: EXPERIMENTAL
Intervention: 0.75% ropivacaine (group R)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normal saline (group NS)
Number of subjects: 30
Study: 26856213

Group type: EXPERIMENTAL
Intervention: Provocative Dyspnea Severity Score (pDS) during upright with O2, upright without O2, and supine without O2 assessments.
Number of subjects: 230

Group type: COMPARATOR
Intervention: Dyspnea Visual Analog Scale (DVAS)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Oxygen withdrawal and supine provocation
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Exercise provocation
Number of subjects: 230
Study: 24557087

Group type: EXPERIMENTAL
Intervention: Sevoflurane/propofol regimen (group SP)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Sevoflurane regimen (group S)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 160
Study: 22344040

Group type: EXPERIMENTAL
Intervention: BARC bleeding definition
Number of subjects: 12459

Group type: COMPARATOR
Intervention: TIMI bleeding definition
Number of subjects: 12459

Group type: COMPARATOR
Intervention: REPLACE-2 bleeding definition
Number of subjects: 12459

Group type: EXPERIMENTAL
Intervention: Overall mortality
Number of subjects: 12459
Study: 19743543

Group type: EXPERIMENTAL
Intervention: Ranolazine (500 mg to 1000 mg twice a day) added to ongoing amlodipine therapy
Number of subjects: 1388

Group type: COMPARATOR
Intervention: Atenolol (beta-blocker)
Number of subjects: 1388

Group type: COMPARATOR
Intervention: Amlodipine (calcium channel blocker)
Number of subjects: 1388
Study: 17557688

Group type: EXPERIMENTAL
Intervention: Coloured overlay
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reading-age controls
Number of subjects: 0
Study: 16480346

Group type: EXPERIMENTAL
Intervention: Laryngeal tube
Number of subjects: 0

Group type: COMPARATOR
Intervention: Laryngeal mask airway
Number of subjects: 0
Study: 15333452

Group type: COMPARATOR
Intervention: Oral lactobacillus
Number of subjects: 278

Group type: COMPARATOR
Intervention: Vaginal lactobacillus
Number of subjects: 278

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 278
Study: 11523750

Group type: EXPERIMENTAL
Intervention: Family-directed program consisting of booklets and follow-up calls by health educators
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study: 8880290

Group type: EXPERIMENTAL
Intervention: Intravenous lysine clonixinate 4 mg x kg‐1
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Intravenous lysine clonixinate 6 mg x kg‐1
Number of subjects: 10
Study: 2059818

Group type: EXPERIMENTAL
Intervention: Duplex ultrasonography
Number of subjects: 65
Study: 6881687

Group type: EXPERIMENTAL
Intervention: Fenoterol aerosol delivered by the patients' own technique
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Fenoterol aerosol delivered under supervision by a trained member of staff
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Fenoterol aerosol delivered with a spacer device (Aerochamber)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo aerosol
Number of subjects: 13
Study: 30202916

Group type: EXPERIMENTAL
Intervention: Daily tobacco consumption (10 g/day increase)
Number of subjects: 103557

Group type: EXPERIMENTAL
Intervention: Cumulative tobacco consumption (10 pack-years increase)
Number of subjects: 103557

Group type: EXPERIMENTAL
Intervention: CHRNA3 rs1051730 genotype (proxy for tobacco consumption)
Number of subjects: 103557
Study: 31143771

Group type: EXPERIMENTAL
Intervention: 635 nm laser (G1)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (G2)
Number of subjects: 24
Study: 28477944

Group type: EXPERIMENTAL
Intervention: High-protein diet (1.7 g/kg per day) during hospitalization, daily protein supplement (18.8 g), and 3 weekly resistance training sessions for 12 weeks after discharge
Number of subjects: 29

Group type: COMPARATOR
Intervention: Standard-care
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: High-protein diet and resistance training
Number of subjects: 29
Study: 25391814

Group type: EXPERIMENTAL
Intervention: Psyllium (7.0 g daily)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Cellulose (equivalent amount to psyllium)
Number of subjects: 51
Study: 23390204

Group type: EXPERIMENTAL
Intervention: Screening arm (intervention)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control arm (control)
Number of subjects: 0
Study: 21664880

Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 18641424

Group type: EXPERIMENTAL
Intervention: Educational intervention (face-to-face education and group seminar in public hospitals; face-to-face education only in private hospitals)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Educational intervention (group seminar)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (face-to-face education only in private hospitals)
Number of subjects: 40
Study: 16636130

Group type: EXPERIMENTAL
Intervention: r‐metHuLeptin therapy
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 12801313

Group type: EXPERIMENTAL
Intervention: montelukast 10 mg/desloratadine 5 mg combination
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: montelukast 10 mg alone
Number of subjects: 15

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: montelukast/desloratadine
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: montelukast
Number of subjects: 15
Study: 10824413

Group type: EXPERIMENTAL
Intervention: Lyophilized Enterococcus faecium M‐74 in the form of waffles (Dr. Ebi)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (waffles without active ingredient)
Number of subjects: 0
Study: 8852914

Group type: EXPERIMENTAL
Intervention: Oral acyclovir therapy (300 mg/m2/dose, administered either twice daily or three times per day for 6 months)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Oral acyclovir therapy
Number of subjects: 26
Study: 1497125

Group type: EXPERIMENTAL
Intervention: Fentanyl (5 micrograms/kg bolus, 2 micrograms kg‐1 h‐1 infusion)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Pentazocine (2 mg/kg bolus, 0.8 mg kg‐1 h‐1 infusion)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ketamine (2 mg/kg bolus, 0.8 mg kg‐1 h‐1 infusion)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Enflurane (0.5‐2 vol.% added if insufficient anaesthesia)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Post-operative recovery and pain monitored using verbal rating scales
Number of subjects: 60
Study: 6140128

Group type: EXPERIMENTAL
Intervention: 100 mg tiapride 3-times daily for 14 days
Number of subjects: 42

Group type: COMPARATOR
Intervention: 200 mg glafenine 3-times daily for 14 days
Number of subjects: 42
Study: 30854728

Group type: COMPARATOR
Intervention: Transcranial direct current stimulation (tDCS) applied to primary sensory-motor hand regions (anode left, cathode right)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Transcranial direct current stimulation (tDCS)
Number of subjects: 15
Study: 27916737

Group type: EXPERIMENTAL
Intervention: SSB+SCB (n=30): 15mL of bupivacaine 0.25% for SSB and 15mL of bupivacaine 0.25% for SCB
Number of subjects: 60

Group type: COMPARATOR
Intervention: ISB (n=30): 30mL of bupivacaine 0.25%
Number of subjects: 60
Study: 27326239

Group type: COMPARATOR
Intervention: Riociguat (maximum 2.5 mg three times daily or 1.5 mg three times daily in PATENT‐1; maximum 2.5 mg three times daily in CHEST‐1)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Riociguat
Number of subjects: 109
Study: 25059727

Group type: EXPERIMENTAL
Intervention: Intracuff pressure of 60 cm H2 O
Number of subjects: 36

Group type: COMPARATOR
Intervention: Intracuff pressure of 40 cm H2 O
Number of subjects: 36

Group type: COMPARATOR
Intervention: Intracuff pressure of 80 cm H2 O
Number of subjects: 36
Study: 22433921

Group type: EXPERIMENTAL
Intervention: Rabeprazole (RPZ) 20 mg b.i.d.
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: Rabeprazole (RPZ) 10 mg b.i.d.
Number of subjects: 337

Group type: COMPARATOR
Intervention: Rabeprazole (RPZ) 20 mg q.d. (control)
Number of subjects: 337
Study: 19505390

Group type: EXPERIMENTAL
Intervention: Nebulized flunisolide (40 microg/kg twice daily for 7 days, then 20 microg/kg twice daily for 14 days)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Nebulized budesonide (0.5 mg twice daily for 7 days, then 0.25 mg twice daily for 15 days)
Number of subjects: 46
Study: 17440205

Group type: EXPERIMENTAL
Intervention: Induced anger
Number of subjects: 3
Study: 15893621

Group type: COMPARATOR
Intervention: Td vaccine
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: TdaP vaccine
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: TdaP-IPV (Aventis Pasteur)
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: TdaP (GlaxoSmithKline)
Number of subjects: 323
Study: 11682426

Group type: EXPERIMENTAL
Intervention: Inflatable pillows (Shoulder‐Float) beneath the chest wall and head
Number of subjects: 15

Group type: COMPARATOR
Intervention: Gel-pad
Number of subjects: 15

Group type: COMPARATOR
Intervention: 1000-mL lactated Ringer's bag
Number of subjects: 15
Study: 9458425

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study: 7936893

Group type: EXPERIMENTAL
Intervention: Bundled infants (n = 36)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control infants (n = 28)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Comparison of bundled infants to nonbundled controls
Number of subjects: 64
Study: 3154312

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Nicardipine
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Tiapamil
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 63
Study: 30340917

Group type: EXPERIMENTAL
Intervention: Allostatic load (AL) measured at baseline
Number of subjects: 106
Study: 29134964

Group type: EXPERIMENTAL
Intervention: High Definition (HD) colonoscopy
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Virtual Chromoendoscopy (VCE)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Dye Spraying Chromoendoscopy (DCE)
Number of subjects: 270
Study: 27314584

Group type: EXPERIMENTAL
Intervention: Full interactive pre-MRI instruction (n=64)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Partial instruction (n=57)
Number of subjects: 121
Study: 25607740

Group type: EXPERIMENTAL
Intervention: Fresh RBCs (7-15 days storage)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: RBCs (25-38 days storage)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: RBCs (16-24 days storage)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Washed RBCs (> 27 days storage)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Unwashed RBCs
Number of subjects: 128
Study: 24090294

Group type: EXPERIMENTAL
Intervention: Audiovisual distraction
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group (no audiovisual distraction)
Number of subjects: 84
Study: 20664121

Group type: EXPERIMENTAL
Intervention: Simulated 'positive' study (showing adverse fetal effects)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Simulated 'negative' study (showing no adverse fetal effects)
Number of subjects: 0
Study: 18258628

Group type: EXPERIMENTAL
Intervention: Brazil nuts
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Selenomethionine
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59